Global In-vitro Fertilization Market Research Report – Forecast to 2023

$4,450$6,250

Clear

Description

In-vitro fertilization (IVF) has become an established treatment option for different forms of infertility. IVF procedures help infertile people to conceive. IVF provides women the opportunity to become pregnant using her own eggs or donor’s eggs and sperm from her partner or from a sperm donor. As the IVF procedure is quite expensive, people generally try out other options. In case of failure in other treatments, IVF remains as the only option for the people longing to experience parenthood. Additionally, in certain cases, IVF is chosen if the parents are fearful of passing certain genetic disorders to the child. The embryos can be tested for genetic abnormalities in medical labs prior to implantation.
The factors such as the rise in the rate of infertility and surrogacy in developing countries, increasing occurrence of reproductive tourism, and high success rate of IVF are anticipated to be the drivers for the growth of the market. Additionally, the changing lifestyle in urban areas and increased age of parenthood are expected to boost the growth of the market. Despite the drivers, the high cost related to assisted reproductive techniques (ART) may hamper the growth of the global in-vitro fertilization market.
The global in-vitro fertilization market has been segmented based on product, type, end-user, and region.
Based on product, the market is segmented into devices and reagents. The devices segment is further segmented into imaging systems, sperm separation system, ovum aspiration pump, cerosystem, and micromanipulator. The reagent segment is segmented into embryo culture media, cryopreservation media, sperm processing media, and ovum processing media.
Based on type, the market is segmented into intrauterine insemination (IUI), in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and IVF using donor eggs.
Based on end-user, the market is segmented into fertility clinics, hospitals, clinical research centers, and others.
The global in-vitro fertilization market is expected to register a CAGR of 10.50% during the forecast period from 2018 to 2023.
Key Players
Cook Medical, Cooper Surgical Fertility, Merck KGaA, Thermo Fisher Scientific, INVO Bioscience, Irvine Scientific, GENEA BIOMEDX, Vitrolife, Oxford Gene Technology, Genea Limited, and others.
Study objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the in-vitro fertilization market
• To provide insights into factors affecting the market growth
• To analyze the global in-vitro fertilization market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide country-level analysis of the market with respect to the current market size and future perspective
• To provide country-level analysis of the market for segments by product, type, end-user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the in-vitro fertilization market

Target Audience
• IVF device manufacturers & suppliers
• Biotechnology companies
• Fertility clinics
• Hospitals & clinics
• Academic research institutes
• Government institutes
Key Findings
• The global in-vitro fertilization market is expected to register a CAGR of 10.50% during the forecast period from 2018 to 2023
• Based on product, the devices segment accounted for the largest market share of 53.5% in 2017, with a market value of USD 3,739.7 million in 2017
• Based on type, the intrauterine insemination (IUI) segment accounted for the largest market share of 35.4% in 2017, with a market value of USD 2,470.3 million
• Europe holds the largest share of the global in-vitro fertilization market which is expected to reach USD 5,074.1 million by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 11.05 % from 2018 to 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

Table of Contents

 

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Increased rate of infertility and high demand for IVF techniques
5.2.2 Gender selection and growing trend of reproductive tourism
5.2.3 Declining fertility rate
5.2.4 Technological advancements in infertility treatments
5.2.5 Increasing prevalence of obesity
5.3 Restraints
5.3.1 High procedural costs of assisted reproductive techniques in developed markets
5.4 Opportunities
5.4.1 Reimbursement for fertility treatments
6 Market Factor Analysis
6.1 Value Chain Analysis
6.1.1 R&D
6.1.2 Manufacturing
6.1.3 Distribution
6.1.4 Marketing & Sales
6.1.5 Post-Sales Monitoring
6.2 Porter’s Five Forces Analysis
6.2.1 Bargaining Power of Suppliers
6.2.2 Bargaining Power of Buyers
6.2.3 Threat of New Entrants
6.2.4 Threat of Substitutes
6.2.5 Intensity of Rivalry
7 Global In-vitro Fertilization Market, by Product
7.1 Overview
7.2 Devices
7.2.1 Imaging Systems
7.2.2 Sperm Separation System
7.2.3 Ovum Aspiration Pump
7.2.4 Cerosystem
7.2.5 Micromanipulator
7.3 Reagents
7.3.1 Embryo Culture Media
7.3.2 Cryopreservation Media
7.3.3 Sperm Processing Media
7.3.4 Ovum Processing Media
8 Global In-vitro Fertilization Market, by Type
8.1 Overview
8.2 Intrauterine Insemination
8.3 In-vitro Fertilization
8.4 Intracytoplasmic Sperm Injection
8.5 IVF Using Donor Eggs
9 Global In-vitro Fertilization Market, by End-User
9.1 Overview
9.2 Fertility Clinics
9.3 Hospitals
9.4 Clinical Research Centers
10 Global In-vitro Fertilization Market, By Region
10.1 Overview
10.2 Europe
10.2.1 Western Europe
10.2.1.1 Germany
10.2.1.2 France
10.2.1.3 UK
10.2.1.4 Italy
10.2.1.5 Spain
10.2.1.6 Rest of Western Europe
10.2.2 Eastern Europe
10.3 Americas
10.3.1 North America
10.3.1.1 US
10.3.1.2 Canada
10.3.2 South America
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Introduction
11.2 Company Share Analysis
11.2.1 Key Strategic Analysis
12 Company Profiles
12.1 Cook Medical
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products/Services Offering
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategy
12.2 Cooper Surgical Fertility
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products/Services Offering
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.2.6 Key Strategy
12.3 Merck KGaA
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products/Services Offering
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.3.6 Key Strategy
12.4 Thermo Fisher Scientific
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products/Services Offering
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.4.6 Key Strategy
12.5 INVO Bioscience
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products/Services Offering
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.5.6 Key Strategy
12.6 Irvine Scientific
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products/Services Offering
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategy
12.7 GENEA BIOMEDX
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products/Services Offering
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategy
12.8 Vitrolife
12.8.1 Company Overview
12.8.2 Financial Overview
12.8.3 Products/Services Offering
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.8.6 Key Strategy
12.9 Oxford Gene Technology
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products/Services Offering
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategy
12.1 Genea Limited
12.10.1 Company Overview
12.10.2 Financial Overview
12.10.3 Products/Services Offering
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.10.6 Key Strategy
13 Appendix
13.1 Discussion Blue Print

Additional information

Publisher

Geography Covered

Date Published

Pages

Format